NASDAQ:ATRC - AtriCure Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$24.16 +0.33 (+1.38 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$24.16
Today's Range$23.61 - $24.31
52-Week Range$14.88 - $25.18
Volume63,200 shs
Average Volume163,034 shs
Market Capitalization$835 million
P/E RatioN/A
Dividend YieldN/A
Beta0.25

About AtriCure (NASDAQ:ATRC)

AtriCure logoAtriCure, Inc. provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery. It also provides SUBTLE cannula, an access device and conduit for the ablation device and endoscope to enable a closed chest endoscopic approach; multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable physicians to create an expanded cardiac ablation lesion set. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. AtriCure sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.

Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ATRC
CUSIP04963C20
Phone513-755-4100

Debt

Debt-to-Equity Ratio0.34
Current Ratio3.15
Quick Ratio2.31

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$174.72 million
Price / Sales4.85
Cash FlowN/A
Price / CashN/A
Book Value$4.37 per share
Price / Book5.53

Profitability

EPS (Most Recent Fiscal Year)($0.83)
Net Income$-26,890,000.00
Net Margins-14.88%
Return on Equity-16.92%
Return on Assets-9.99%

Miscellaneous

Employees570
Outstanding Shares35,040,000

AtriCure (NASDAQ:ATRC) Frequently Asked Questions

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

How were AtriCure's earnings last quarter?

AtriCure (NASDAQ:ATRC) issued its earnings results on Thursday, April, 26th. The medical device company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.04. The medical device company earned $46.99 million during the quarter, compared to analyst estimates of $45.43 million. AtriCure had a negative return on equity of 16.92% and a negative net margin of 14.88%. The business's revenue for the quarter was up 13.9% on a year-over-year basis. During the same period in the previous year, the company earned ($0.32) earnings per share. View AtriCure's Earnings History.

When is AtriCure's next earnings date?

AtriCure is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for AtriCure.

What price target have analysts set for ATRC?

5 equities research analysts have issued 12-month price targets for AtriCure's stock. Their forecasts range from $23.00 to $26.00. On average, they anticipate AtriCure's share price to reach $25.00 in the next twelve months. View Analyst Ratings for AtriCure.

What are Wall Street analysts saying about AtriCure stock?

Here are some recent quotes from research analysts about AtriCure stock:
  • 1. According to Zacks Investment Research, "AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. " (5/2/2018)
  • 2. Needham & Company LLC analysts commented, "ATRC’s 4Q17 revenue was consistent with its 1/8/18 preannouncement while its EBITDA missed consensus and EPS beat consensus even excluding a $0.12 non-cash benefit. Management reiterated its 2018 revenue guidance of $190-196M vs. consensus of $195M. We believe the recent society guidelines, new products (AtriClip Pro-V and Flex-V), and surgeon training activities should drive strong growth. We believe that management’s more conservative guidance leaves room for upside and with ATRC shares trading at a large discount to peers (2018E EV/sales of 3.3x vs. small/mid-cap growth peers at a median of 6.4x), we reiterate our Buy rating." (2/27/2018)

Who are some of AtriCure's key competitors?

Who are AtriCure's key executives?

AtriCure's management team includes the folowing people:
  • Mr. Michael H. Carrel, Chief Exec. Officer, Pres and Director (Age 47)
  • Mr. M. Andrew Wade, Chief Financial Officer and Sr. VP (Age 43)
  • Mr. Douglas J. Seith, Chief Operating Officer (Age 52)
  • Mr. Justin J. Noznesky, Sr. VP of Marketing and Bus. Devel. (Age 40)
  • Mr. Karl Dahlquist, Chief Compliance Officer and VP of Legal & Compliance

Has AtriCure been receiving favorable news coverage?

Headlines about ATRC stock have trended somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AtriCure earned a media sentiment score of 0.13 on Accern's scale. They also gave news headlines about the medical device company an impact score of 46.97 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are AtriCure's major shareholders?

AtriCure's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.48%), Hudson Executive Capital LP (6.78%), First Light Asset Management LLC (3.33%), Millennium Management LLC (2.45%), Loomis Sayles & Co. L P (2.30%) and Neuberger Berman Group LLC (2.23%). Company insiders that own AtriCure stock include Andrew L Lux, B Kristine Johnson, Elizabeth D Krell, Justin J Noznesky, M Andrew Wade and Regina E Groves. View Institutional Ownership Trends for AtriCure.

Which major investors are selling AtriCure stock?

ATRC stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, BlackRock Inc., GSA Capital Partners LLP, Neuberger Berman Group LLC, Wasatch Advisors Inc., Loomis Sayles & Co. L P, Nuveen Asset Management LLC and A.R.T. Advisors LLC. Company insiders that have sold AtriCure company stock in the last year include Elizabeth D Krell, Justin J Noznesky and M Andrew Wade. View Insider Buying and Selling for AtriCure.

Which major investors are buying AtriCure stock?

ATRC stock was acquired by a variety of institutional investors in the last quarter, including Hudson Executive Capital LP, The Manufacturers Life Insurance Company , Millennium Management LLC, First Light Asset Management LLC, Quantum Capital Management, Tamarack Advisers LP, Trexquant Investment LP and Highbridge Capital Management LLC. Company insiders that have bought AtriCure stock in the last two years include B Kristine Johnson and Regina E Groves. View Insider Buying and Selling for AtriCure.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $24.16.

How big of a company is AtriCure?

AtriCure has a market capitalization of $835 million and generates $174.72 million in revenue each year. The medical device company earns $-26,890,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. AtriCure employs 570 workers across the globe.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.


MarketBeat Community Rating for AtriCure (ATRC)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  309 (Vote Outperform)
Underperform Votes:  175 (Vote Underperform)
Total Votes:  484
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe ATRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AtriCure (NASDAQ:ATRC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for AtriCure in the last 12 months. Their average twelve-month price target is $25.00, suggesting that the stock has a possible upside of 3.48%. The high price target for ATRC is $26.00 and the low price target for ATRC is $23.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.862.86
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $25.00$24.80$24.3333$25.00
Price Target Upside: 3.48% upside35.37% upside37.24% upside16.60% upside

AtriCure (NASDAQ:ATRC) Consensus Price Target History

Price Target History for AtriCure (NASDAQ:ATRC)

AtriCure (NASDAQ:ATRC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/27/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$22.00 ➝ $23.00HighView Rating Details
4/27/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$23.00 ➝ $26.00HighView Rating Details
2/27/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$24.00 ➝ $26.00HighView Rating Details
12/10/2017Piper Jaffray CompaniesReiterated RatingBuy$24.00LowView Rating Details
6/16/2017Leerink SwannReiterated RatingOutperform$26.00LowView Rating Details
3/20/2017Northland SecuritiesReiterated RatingBuy$24.00LowView Rating Details
3/6/2017BTIG ResearchDowngradeBuy ➝ NeutralN/AView Rating Details
8/6/2016JMP SecuritiesSet Price TargetBuy$23.00N/AView Rating Details
8/5/2016UBSLower Price TargetSell$15.00 ➝ $14.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

AtriCure (NASDAQ:ATRC) Earnings History and Estimates Chart

Earnings by Quarter for AtriCure (NASDAQ:ATRC)

AtriCure (NASDAQ:ATRC) Earnings Estimates

2018 EPS Consensus Estimate: ($0.87)
2019 EPS Consensus Estimate: ($0.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.29)($0.29)($0.29)
Q2 20181($0.27)($0.27)($0.27)
Q3 20181($0.18)($0.18)($0.18)
Q4 20181($0.13)($0.13)($0.13)
Q1 20191($0.24)($0.24)($0.24)
Q2 20191($0.21)($0.21)($0.21)
Q3 20191($0.12)($0.12)($0.12)
Q4 20191($0.06)($0.06)($0.06)

AtriCure (NASDAQ ATRC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2018($0.23)N/AView Earnings Details
4/26/2018Q1 2018($0.27)($0.31)$45.43 million$46.99 millionViewN/AView Earnings Details
2/26/2018Q4 2017($0.21)($0.08)$45.85 million$46.06 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.24)($0.22)$43.44 million$42.20 millionViewN/AView Earnings Details
7/27/2017Q2 2017($0.26)($0.2130)$44.15 million$45.23 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.33)($0.32)$40.25 million$41.30 millionViewListenView Earnings Details
2/28/2017Q4 2016($0.3180)($0.27)$41.17 million$41.20 millionViewListenView Earnings Details
10/27/2016Q316($0.28)($0.21)$10.75 million$38.34 millionViewListenView Earnings Details
8/4/2016Q216($0.30)($0.26)$39.84 million$39.70 millionViewListenView Earnings Details
4/28/2016Q116($0.32)($0.31)$36.08 million$35.90 millionViewListenView Earnings Details
2/23/2016Q415($0.36)($0.36)$35.90 million$35.90 millionViewListenView Earnings Details
10/27/2015Q315($0.22)($0.22)$31.32 million$31.40 millionViewListenView Earnings Details
7/28/2015Q215($0.21)($0.18)$30.51 million$32.58 millionViewListenView Earnings Details
4/29/2015Q115($0.21)($0.19)$28.65 million$29.90 millionViewListenView Earnings Details
2/23/2015Q414($0.20)($0.20)$28.40 million$29.40 millionViewListenView Earnings Details
10/30/2014Q314($0.17)($0.02)$25.60 million$26.70 millionViewListenView Earnings Details
7/24/2014Q214($0.19)($0.10)$25.03 million$26.51 millionViewListenView Earnings Details
4/24/2014Q114($0.22)($0.31)$23.36 million$24.80 millionViewListenView Earnings Details
2/27/2014Q413($0.14)($0.24)$21.16 million$21.90 millionViewListenView Earnings Details
10/29/2013Q313($0.15)($0.13)$18.30 million$20.10 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.10)($0.09)$19.42 million$20.40 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.09)($0.10)$18.63 million$19.43 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.09)($0.12)$18.46 million$18.40 millionViewListenView Earnings Details
11/1/2012Q312($0.11)($0.16)$17.29 million$16.10 millionViewN/AView Earnings Details
8/2/2012($0.07)($0.08)ViewN/AView Earnings Details
5/2/2012($0.13)($0.10)ViewN/AView Earnings Details
2/27/2012Q4 2011($0.07)($0.13)ViewN/AView Earnings Details
11/1/2011($0.07)($0.07)ViewN/AView Earnings Details
8/2/2011($0.01)($0.06)ViewN/AView Earnings Details
5/4/2011Q1 2011($0.07)($0.08)ViewN/AView Earnings Details
11/2/2010Q3 2010($0.10)($0.07)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.12)($0.05)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.09)($0.13)ViewN/AView Earnings Details
2/18/2010Q4 2009($0.09)($0.15)ViewN/AView Earnings Details
11/4/2009Q3 2009($0.09)($0.06)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.08)($0.08)ViewN/AView Earnings Details
5/5/2009Q1 2009($0.18)($0.08)ViewN/AView Earnings Details
2/19/2009Q4 2008($0.16)($0.16)ViewN/AView Earnings Details
11/4/2008Q3 2008($0.16)($0.12)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.18)($0.11)ViewN/AView Earnings Details
5/6/2008Q1 2008($0.23)($0.25)ViewN/AView Earnings Details
2/14/2008Q4 2007($0.20)($0.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AtriCure (NASDAQ:ATRC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

AtriCure (NASDAQ ATRC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 87.56%
Insider Trading History for AtriCure (NASDAQ:ATRC)
Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

AtriCure (NASDAQ ATRC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/8/2018Elizabeth D KrellDirectorSell10,000$22.82$228,200.0029,967View SEC Filing  
3/13/2018Elizabeth D KrellDirectorSell10,000$20.00$200,000.00View SEC Filing  
3/1/2018Regina E GrovesDirectorBuy1,000$17.43$17,430.00View SEC Filing  
2/15/2018Justin J NozneskySVPSell4,000$17.03$68,120.00View SEC Filing  
11/30/2017M. Andrew WadeCFOSell2,000$18.41$36,820.00View SEC Filing  
11/8/2017B Kristine JohnsonDirectorBuy1,500$18.36$27,540.0010,969View SEC Filing  
8/22/2017Elizabeth D KrellDirectorSell10,000$22.40$224,000.0029,967View SEC Filing  
5/17/2017Elizabeth D KrellDirectorSell10,000$21.44$214,400.0024,162View SEC Filing  
3/17/2017Andrew L LuxSVPSell20,000$18.85$377,000.0085,589View SEC Filing  
11/15/2016Elizabeth D KrellDirectorSell10,000$19.73$197,300.0024,162View SEC Filing  
9/13/2016Elizabeth D KrellDirectorSell6,000$15.93$95,580.0020,162View SEC Filing  
8/17/2016Elizabeth D KrellDirectorSell5,000$15.20$76,000.0015,162View SEC Filing  
3/8/2016Elizabeth D KrellDirectorSell10,000$16.91$169,100.0017,162View SEC Filing  
12/3/2015Douglas J. SeithCOOSell5,000$21.55$107,750.00125,215View SEC Filing  
12/2/2015Elizabeth D. KrellDirectorSell10,000$21.88$218,800.007,162View SEC Filing  
11/11/2015Elizabeth D. KrellDirectorSell10,000$20.68$206,800.007,162View SEC Filing  
4/1/2015Michael D HoovenDirectorSell142,268$20.81$2,960,597.08View SEC Filing  
3/31/2015Michael D HoovenDirectorSell20,000$20.51$410,200.00View SEC Filing  
3/30/2015Michael D HoovenDirectorSell85,000$21.01$1,785,850.00View SEC Filing  
3/13/2015Karen P RobardsDirectorSell3,150$19.53$61,519.50View SEC Filing  
3/5/2015Douglas J SeithCOOSell36,688$17.51$642,406.88View SEC Filing  
3/2/2015Elizabeth D KrellDirectorSell10,000$17.63$176,300.00View SEC Filing  
5/6/2014Douglas SeithSVPBuy1,000$15.04$15,040.0095,694View SEC Filing  
9/13/2013Richard JohnstonInsiderSell77,610$10.00$776,100.00View SEC Filing  
8/12/2013Douglas SeithSVPBuy10,000$9.58$95,800.0058,240View SEC Filing  
8/5/2013Richard JohnstonInsiderSell20,047$10.00$200,470.00View SEC Filing  
7/11/2013Richard M JohnstonInsiderSell2,343$10.00$23,430.00View SEC Filing  
6/19/2013Richard M JohnstonInsiderSell29,348$8.96$262,958.08View SEC Filing  
6/18/2013Richard M JohnstonInsiderSell39,682$9.18$364,280.76View SEC Filing  
6/14/2013Richard M JohnstonInsiderSell95,598$8.97$857,514.06View SEC Filing  
6/12/2013Richard M JohnstonInsiderSell35,372$9.01$318,701.72View SEC Filing  
3/6/2013James L LuckyVPSell50,065$8.14$407,529.10View SEC Filing  
9/14/2012Mark R LanningDirectorBuy11,006$7.64$84,085.84View SEC Filing  
9/13/2012Michael D HoovenDirectorBuy1,110$7.37$8,180.70View SEC Filing  
9/12/2012Michael D HoovenDirectorBuy1,150$7.10$8,165.00View SEC Filing  
9/11/2012Michael D HoovenDirectorBuy1,145$7.18$8,221.10View SEC Filing  
9/10/2012Michael D HoovenDirectorBuy1,215$7.15$8,687.25View SEC Filing  
9/7/2012Michael D HoovenDirectorBuy1,215$6.88$8,359.20View SEC Filing  
8/23/2012Karen P RobardsDirectorBuy1,000$6.70$6,700.00View SEC Filing  
8/16/2012Karen P RobardsDirectorBuy1,000$6.98$6,980.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AtriCure (NASDAQ ATRC) News Headlines

Source:
DateHeadline
AtriCure (ATRC) Expected to Post Quarterly Sales of $49.85 MillionAtriCure (ATRC) Expected to Post Quarterly Sales of $49.85 Million
www.americanbankingnews.com - May 25 at 2:00 AM
-$0.22 Earnings Per Share Expected for AtriCure (ATRC) This Quarter-$0.22 Earnings Per Share Expected for AtriCure (ATRC) This Quarter
www.americanbankingnews.com - May 23 at 7:08 PM
AtriCure (ATRC) Given Average Rating of "Buy" by BrokeragesAtriCure (ATRC) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 21 at 9:38 AM
AtriCure (ATRC) Upgraded to Strong-Buy at BidaskClubAtriCure (ATRC) Upgraded to Strong-Buy at BidaskClub
www.americanbankingnews.com - May 19 at 1:00 PM
AtriCure (ATRC) Lifted to "Buy" at ValuEngineAtriCure (ATRC) Lifted to "Buy" at ValuEngine
www.americanbankingnews.com - May 12 at 5:05 PM
Global Ablation Market Overview 2017-2026: AtriCure Inc, Boston Scientific Corporation, CONMED Corporation, Smith & NephewGlobal Ablation Market Overview 2017-2026: AtriCure Inc, Boston Scientific Corporation, CONMED Corporation, Smith & Nephew
www.marketwatch.com - May 11 at 8:38 AM
Global Ablation Market Competitive landscape: Boston Scientific Corporation, AtriCure IncGlobal Ablation Market Competitive landscape: Boston Scientific Corporation, AtriCure Inc
www.marketwatch.com - May 10 at 5:48 PM
AtriCure (ATRC) Director Sells $228,200.00 in StockAtriCure (ATRC) Director Sells $228,200.00 in Stock
www.americanbankingnews.com - May 9 at 10:12 AM
$49.85 Million in Sales Expected for AtriCure (ATRC) This Quarter$49.85 Million in Sales Expected for AtriCure (ATRC) This Quarter
www.americanbankingnews.com - May 8 at 3:36 AM
Zacks: Brokerages Expect AtriCure (ATRC) Will Post Earnings of -$0.22 Per ShareZacks: Brokerages Expect AtriCure (ATRC) Will Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - May 6 at 11:31 AM
AtriCure (ATRC) Upgraded by ValuEngine to "Buy"AtriCure (ATRC) Upgraded by ValuEngine to "Buy"
www.americanbankingnews.com - May 5 at 2:27 PM
Head-To-Head Comparison: Neovasc (NVCN) & AtriCure (ATRC)Head-To-Head Comparison: Neovasc (NVCN) & AtriCure (ATRC)
www.americanbankingnews.com - May 4 at 11:15 AM
AtriCure (ATRC) Downgraded to "Hold" at Zacks Investment ResearchAtriCure (ATRC) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 2 at 6:06 PM
AtriCure (ATRC) Upgraded to Buy by Zacks Investment ResearchAtriCure (ATRC) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - May 1 at 7:10 PM
AtriCures (ATRC) CEO Mike Carrel on Q1 2018 Results - Earnings Call TranscriptAtriCure's (ATRC) CEO Mike Carrel on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 29 at 8:04 AM
Edited Transcript of ATRC earnings conference call or presentation 26-Apr-18 8:30pm GMTEdited Transcript of ATRC earnings conference call or presentation 26-Apr-18 8:30pm GMT
finance.yahoo.com - April 28 at 8:05 AM
Heres why AtriCure stock is surgingHere's why AtriCure stock is surging
www.bizjournals.com - April 27 at 5:27 PM
Here's why AtriCure stock is surgingHere's why AtriCure stock is surging
finance.yahoo.com - April 27 at 5:27 PM
AtriCure (ATRC) Releases Quarterly  Earnings Results, Misses Expectations By $0.04 EPSAtriCure (ATRC) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS
www.americanbankingnews.com - April 27 at 2:38 PM
AtriCure (ATRC) Price Target Increased to $26.00 by Analysts at Needham & Company LLCAtriCure (ATRC) Price Target Increased to $26.00 by Analysts at Needham & Company LLC
www.americanbankingnews.com - April 27 at 11:27 AM
AtriCure (ATRC) Price Target Raised to $23.00 at Stifel NicolausAtriCure (ATRC) Price Target Raised to $23.00 at Stifel Nicolaus
www.americanbankingnews.com - April 27 at 11:21 AM
AtriCure: 1Q Earnings SnapshotAtriCure: 1Q Earnings Snapshot
finance.yahoo.com - April 27 at 8:03 AM
AtriCure Reports First Quarter 2018 Financial ResultsAtriCure Reports First Quarter 2018 Financial Results
finance.yahoo.com - April 26 at 5:29 PM
AtriCure (ATRC) Given Consensus Rating of "Buy" by AnalystsAtriCure (ATRC) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 26 at 10:10 AM
AtriCure (ATRC) Scheduled to Post Quarterly Earnings on WednesdayAtriCure (ATRC) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 25 at 5:28 AM
Reviewing AtriCure (ATRC) & Nuvectra (NVTR)Reviewing AtriCure (ATRC) & Nuvectra (NVTR)
www.americanbankingnews.com - April 24 at 3:16 PM
AtriCure (ATRC) Expected to Announce Quarterly Sales of $45.77 MillionAtriCure (ATRC) Expected to Announce Quarterly Sales of $45.77 Million
www.americanbankingnews.com - April 21 at 4:20 AM
AtriCure (ATRC) Expected to Announce Earnings of -$0.26 Per ShareAtriCure (ATRC) Expected to Announce Earnings of -$0.26 Per Share
www.americanbankingnews.com - April 19 at 9:51 AM
BidaskClub Downgrades AtriCure (ATRC) to BuyBidaskClub Downgrades AtriCure (ATRC) to Buy
www.americanbankingnews.com - April 16 at 7:00 PM
Is There Now An Opportunity In AtriCure Inc (NASDAQ:ATRC)?Is There Now An Opportunity In AtriCure Inc (NASDAQ:ATRC)?
finance.yahoo.com - April 10 at 5:47 PM
Free Post Earnings Research Report: AtriCure’s Quarterly Revenues Jumped 11.9%; Net Loss NarrowedFree Post Earnings Research Report: AtriCure’s Quarterly Revenues Jumped 11.9%; Net Loss Narrowed
finance.yahoo.com - April 9 at 8:22 AM
AtriCure Inc. (ATRC) Expected to Post Quarterly Sales of $45.77 MillionAtriCure Inc. (ATRC) Expected to Post Quarterly Sales of $45.77 Million
www.americanbankingnews.com - April 4 at 3:58 AM
-$0.26 EPS Expected for AtriCure Inc. (ATRC) This Quarter-$0.26 EPS Expected for AtriCure Inc. (ATRC) This Quarter
www.americanbankingnews.com - April 2 at 9:12 AM
AtriCure (ATRC) Given New $25.00 Price Target at Needham & Company LLCAtriCure (ATRC) Given New $25.00 Price Target at Needham & Company LLC
www.americanbankingnews.com - April 2 at 8:39 AM
AtriCure (ATRC) Given New $24.00 Price Target at Canaccord GenuityAtriCure (ATRC) Given New $24.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - April 1 at 10:52 PM
AtriCure Inc. (ATRC) Given Average Rating of "Buy" by BrokeragesAtriCure Inc. (ATRC) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 1 at 9:36 AM
AtriCures (ATRC) Buy Rating Reiterated at Needham & Company LLCAtriCure's (ATRC) Buy Rating Reiterated at Needham & Company LLC
www.americanbankingnews.com - March 28 at 2:06 PM
AtriCure (ATRC) Given New $26.00 Price Target at Canaccord GenuityAtriCure (ATRC) Given New $26.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - March 24 at 9:30 PM
AtriCure (ATRC) Upgraded at TheStreetAtriCure (ATRC) Upgraded at TheStreet
www.americanbankingnews.com - March 24 at 12:28 AM
AtriCure (ATRC) versus Rockwell Medical (RMTI) Critical ComparisonAtriCure (ATRC) versus Rockwell Medical (RMTI) Critical Comparison
www.americanbankingnews.com - March 20 at 3:19 AM
AtriCure (ATRC) Upgraded at BidaskClubAtriCure (ATRC) Upgraded at BidaskClub
www.americanbankingnews.com - March 17 at 3:54 PM
Zacks: Analysts Expect AtriCure Inc. (ATRC) Will Announce Earnings of -$0.26 Per ShareZacks: Analysts Expect AtriCure Inc. (ATRC) Will Announce Earnings of -$0.26 Per Share
www.americanbankingnews.com - March 16 at 7:33 AM
AtriCure to Present at the Needham & Company’s 17th Annual Healthcare ConferenceAtriCure to Present at the Needham & Company’s 17th Annual Healthcare Conference
finance.yahoo.com - March 15 at 9:12 AM
Elizabeth D. Krell Sells 10,000 Shares of AtriCure Inc. (ATRC) StockElizabeth D. Krell Sells 10,000 Shares of AtriCure Inc. (ATRC) Stock
www.americanbankingnews.com - March 14 at 7:49 PM
SeaSpine (SPNE) & AtriCure (ATRC) Head to Head ReviewSeaSpine (SPNE) & AtriCure (ATRC) Head to Head Review
www.americanbankingnews.com - March 12 at 3:10 AM
Meridian Bioscience (VIVO) versus AtriCure (ATRC) Head-To-Head ReviewMeridian Bioscience (VIVO) versus AtriCure (ATRC) Head-To-Head Review
www.americanbankingnews.com - March 10 at 4:18 PM
Active-Investors: Free Research Report as ConforMIS Reported Better Than Expected ResultsActive-Investors: Free Research Report as ConforMIS Reported Better Than Expected Results
www.finanznachrichten.de - March 9 at 9:21 AM
Free Research Report as ConforMIS Reported Better Than Expected ResultsFree Research Report as ConforMIS Reported Better Than Expected Results
finance.yahoo.com - March 9 at 9:21 AM
AtriCure Inc. (ATRC) Given Average Recommendation of "Buy" by BrokeragesAtriCure Inc. (ATRC) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 7 at 2:02 PM
AtriCure Inc. (ATRC) Position Raised by Tamarack Advisers LPAtriCure Inc. (ATRC) Position Raised by Tamarack Advisers LP
www.americanbankingnews.com - March 6 at 10:30 AM

SEC Filings

AtriCure (NASDAQ:ATRC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AtriCure (NASDAQ:ATRC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AtriCure (NASDAQ ATRC) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.